| abstract |
The invention relates to the field of human immunology and medicine, more specifically, to specific active immunotherapy of malignant tumors that depend on TGFα during their growth, and to the treatment of other TGFα-dependent diseases by using a vaccine preparation that can cause an immunological suppression reaction of autologous TGFα. The invention also relates to a method for producing a vaccine preparation, which includes a combination of TGFα and other EGF-R ligands, such as epidermal growth factor (EGF), and which is capable of inhibiting proliferation in tumors, the progression of which depends on these growth factors. This makes it possible to avoid tumor resistance to vaccines containing each of these molecules individually. |